MannKind Corp looks beyond inhaled insulin as pipeline ambitions grow
MannKind Corp is expanding its pipeline beyond its inhaled insulin product, Afrezza, by seeking new therapeutic applications for its Technosphere drug-delivery platform. While Afrezza remains the commercial foundation, the company is exploring other indications like pulmonary arterial hypertension, aiming for rapid systemic drug delivery. This strategy focuses on diversifying its portfolio and leveraging its core technology to complement its established diabetes business.
MannKind (MNKD) Receives a Grant from Breakthrough T1D
MannKind Corporation (MNKD) received a grant from Breakthrough T1D to support its INHALE-1ST clinical trial, which evaluates inhaled insulin in newly diagnosed pediatric patients with type 1 diabetes. This grant provides external validation for Afrezza, MannKind's inhaled insulin product, and comes after a recent FDA approval for its use in children as young as six. The company's stock has shown positive movement following these developments.
MannKind (MNKD) Receives a Grant from Breakthrough T1D
MannKind Corporation (MNKD) received a grant from Breakthrough T1D to support its INHALE-1ST clinical trial, which evaluates inhaled insulin in pediatric type 1 diabetes patients. This grant, along with recent FDA approval for Afrezza in younger children, validates the potential of the company's inhaled insulin product. MNKD's stock has seen a positive performance following the announcement.
Enterprise value to EBIT forward of MannKind Corporation – NASDAQ:MNKD
This article provides financial information for MannKind Corporation (NASDAQ: MNKD), specifically its enterprise value to EBIT forward ratio. It's concise and is part of a larger financial data platform.
Enterprise value to EBITDA forward of MannKind Corporation – NASDAQ:MNKD
This article provides financial data for MannKind Corporation (NASDAQ: MNKD), specifically focusing on its enterprise value to EBITDA forward metric. The content appears to be a financial snapshot from a trading platform, indicating the current market status and offering various financial and community tools related to the stock.
Price to earnings forward of MannKind Corporation – BX:NNFN
This page provides financial information for MannKind Corporation (BX:NNFN) on BX Swiss, specifically focusing on its forward price-to-earnings ratio. The market is currently closed with no trades. The content highlights a specific financial metric for the company.
Enterprise value to revenue forward of MannKind Corporation – NASDAQ:MNKD
This article provides financial snapshot of MannKind Corporation (NASDAQ: MNKD) focusing on its enterprise value to revenue forward. It appears to be an excerpt or a data point from a larger financial analysis platform, likely TradingView, indicating that the market for MNKD is currently closed with no trades.
MannKind shares, Friday focus on the U.S. listing
MannKind Corp (MNKD) shares are closing the week with a focus on their U.S. listing on Nasdaq, with the article discussing the broader U.S. market context and the company's inhaled therapy business. Despite a mixed U.S. market session, attention remains on healthcare names like MannKind, whose mid-cap biotech status means liquidity and sector sentiment are key. The company's core business revolves around inhaled therapeutic products, including Afrezza for diabetes, with its shares last trading at 0.00 USD.
MannKind Corporation Actuals & Estimates (BX:NNFN)
This article provides an overview of MannKind Corporation's financial actuals and estimates, including its stock ticker (NNFN on BX Swiss), analyst forecasts, historical price dynamics, market capitalization, and upcoming earnings date. It also details the company's latest revenue, net income, EBITDA, and employee count, clarifying that it does not pay dividends.
MannKind Corp (MNKD) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of MannKind Corp (MNKD), noting its current price momentum score and suggesting suitability for range-bound swing trading as it trades between resistance at $4.17 and support at $3.41. It presents a summary of technical indicators and moving averages, with overall signals leaning towards "Buy" based on these metrics. The analysis includes details on MACD, RSI, KDJ, and various moving averages from MA5 to MA200.
Afrezza Pediatric Trial Grant Might Change The Case For Investing In MannKind (MNKD)
MannKind Corporation received a grant from Breakthrough T1D for its INHALE-1 clinical study of Afrezza in pediatric type 1 diabetes patients. This funding, combined with recent FDA approval for children, de-risks pediatric Afrezza development and presents a growth opportunity. Investors should consider the potential for increased R&D and commercial spending and analyze additional financial data to form their own investment verdict.
Breakthrough T1D backs MannKind’s pediatric Afrezza trial
MannKind Corporation has received a grant from Breakthrough T1D to support its INHALE-1ST clinical trial for Afrezza in pediatric patients newly diagnosed with type 1 diabetes. This multi-center study will evaluate the safety and efficacy of Afrezza, an ultra rapid-acting inhaled insulin, combined with basal insulin in youth aged 10 to <18. The grant amplifies the recent FDA approval of inhaled insulin for pediatric use and highlights the growing interest in advanced therapeutic options for managing T1D in children.
MannKind Awarded Breakthrough T1D Grant to Support Accessibility
MannKind Corporation has been awarded a grant from Breakthrough T1D (formerly JDRF) to support its INHALE-1ST clinical study. This study evaluates the use of Afrezza (insulin human) Inhalation Powder in newly-diagnosed pediatric patients with type 1 diabetes. The grant reinforces the importance of advancing new therapeutic options for pediatric diabetes care, building on Afrezza's recent FDA approval for pediatric use.
MannKind Corp (MNKD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for MannKind Corp (MNKD) based on business segments and regional contributions. For FY2023, product sales accounted for 62.05% ($216.52M), royalties for 36.71% ($128.12M), and services for 1.24% ($4.33M) of the total revenue. All reported revenue for FY2023 came from the United States, representing 100% of the company's regional revenue.
MannKind Corp (MNKD) Institutional Confidence
MannKind Corp (MNKD) has an institutional shareholding score of 5.00, placing it 133rd in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 17.51% quarter-over-quarter to 67.28%. James Simons is noted as the largest institutional shareholder, though his holdings decreased by 0.79%.
Why MannKind (MNKD) Is Up 8.4% After New Afrezza Pediatric Approval And ADA Data Release
MannKind Corporation (MNKD) saw an 8.4% increase after announcing new clinical data for its inhaled insulin, Afrezza, and FUROSCIX at the American Diabetes Association’s 2026 Scientific Sessions, following the U.S. FDA's May 2026 approval of Afrezza for pediatric use. This data and approval are expected to influence MannKind's investment narrative by expanding the potential market for its Technosphere platform and diversifying its product uses beyond current applications, though the company still faces concentration risk with its primary revenue drivers. Analysts project significant revenue and earnings growth by 2029, suggesting a substantial upside to its current price.
MannKind Corp (MNKD) Financial Health: Profitability & Balance Sheet Analysis
MannKind Corp (MNKD) has a current financial score of 7.73, ranking 86th out of 389 in the Biotechnology & Medical Research industry, indicating weak financial status but high operating efficiency. The company's latest quarterly revenue increased by 15.08% year-over-year to $90.17M, with net profit surging by 226.30%. However, specific data for Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns have not yet been disclosed by the company.
MannKind Corp (MNKD) Earnings Forecast: Future EPS & Revenue Growth Estimates
MannKind Corp (MNKD) has an earnings forecast score of 8.25, ranking 143 out of 388 in its industry, with an average analyst price target of $9.00. Based on 8 analysts, the stock receives a "Buy" rating with a target upside of 96.22%. The company's expected revenue for the next quarter is $109.21M, and its EPS for the previous quarter matched market expectations at -$0.05.
Wells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story”
Wells Fargo recently raised its price target on MannKind Corporation (MNKD) to $11 from $10, reiterating an Overweight rating, following the FDA's approval of Afrezza for pediatric patients. This approval, expanding Afrezza's use to children aged 6 and older with type 1 and type 2 diabetes, positions MannKind with significant commercial potential, termed a "show-me story" by Wells Fargo. MannKind also stands to receive development milestones and royalties from its Tyvaso DPI manufacturing agreement, with its CEO highlighting the company's evolving strength.
7 Hidden Penny Stocks to Invest In
This article highlights MannKind Corporation (NASDAQ:MNKD) as one of seven hidden penny stocks to consider. The biopharmaceutical company recently received FDA approval for its Afrezza Inhalation Powder in pediatric patients and has potential for significant development milestones and royalties. Despite its growth potential, the article suggests that some AI stocks may offer higher returns with less risk.
MannKind (MNKD) Stock And Valuation After New Afrezza And FUROSCIX Clinical Data
MannKind (MNKD) is gaining investor attention after recent positive clinical data for Afrezza and FUROSCIX, alongside pediatric FDA approval for Afrezza. Despite a recent 35.38% share price rebound over 90 days, the year-to-date return is still down 33.04%. The company is considered 47.7% undervalued at its current price of $3.75 compared to a narrative fair value of $7.17, driven by projected accelerated market penetration for Afrezza and progress in its inhaled pipeline.
MannKind gains FDA nod to expand inhaled insulin for children
MannKind Corporation has received FDA approval to expand the label for its Afrezza inhaled insulin. This expansion now includes children and adolescents aged four to 17 with diabetes, making Afrezza the first inhaled insulin option for a pediatric population. The company plans to continue research to better understand treatment patterns and patient perception in this age group.
ADA 2026 data highlight pediatric outcomes and treatment satisfaction with Afrezza
New analyses from the ADA 2026 Scientific Sessions indicate that Afrezza, an inhaled insulin, provides comparable glycemic control, a favorable safety profile, and higher treatment satisfaction in children and adolescents with diabetes. The INHALE-1 study subgroup analyses highlighted its benefits for this age group, including less weight gain and no significant difference in pulmonary function or hypoglycemia compared to subcutaneous insulin. These findings support Afrezza as a valuable option for managing type 1 diabetes in pediatric patients, particularly teenagers, by simplifying insulin administration and offering flexibility.
Should Afrezza Pediatric Approval And New Data Shift MannKind’s (MNKD) Technosphere Platform Investment Narrative?
MannKind (MNKD) recently announced FDA approval of Afrezza for children aged 6 and older, alongside new clinical data for Afrezza and FUROSCIX. This progress, including the advancement of nintedanib DPI into Phase 2 trials for idiopathic pulmonary fibrosis, could significantly alter MannKind's investment narrative by diversifying its revenue streams and reducing dependence on a narrow set of commercial offerings. However, the company still faces challenges with Afrezza's adult adoption and ongoing operating losses.
ADA26: T1 and T2 diabetes readouts from Roche, MannKind and Lilly
The American Diabetes Association (ADA) conference 2026 featured significant readouts in type 1 and type 2 diabetes. Roche's acmopatide showed promise in T1D by reducing A1C levels and insulin requirements while aiding weight loss. MannKind's inhaled insulin Afrezza received FDA approval for pediatric patients and demonstrated improved treatment satisfaction and comparable efficacy to rapid-acting insulin analogues. Amgen's Repatha reduced cardiovascular event risk in high-risk diabetes patients, and Lilly provided detailed data on retatrutide's efficacy in T2D for A1C reduction and metabolic improvements.
Jim Cramer Says He Blessed MannKind as a Speculation Only
Jim Cramer commented on MannKind Corporation (NASDAQ: MNKD) during a Mad Money lightning round, approving it solely as a "speculation" stock. He emphasized that investors should balance speculative plays like MannKind with more earnings-oriented investments. MannKind is a biopharmaceutical company focused on inhaled therapies and delivery devices for chronic conditions.
ADA26: T1 and T2 diabetes readouts from Roche, MannKind and Lilly
At the American Diabetes Association (ADA) conference 2026, Roche, MannKind Corporation, and Lilly presented significant data on Type 1 and Type 2 diabetes treatments. Roche's acmopatide showed improved glucose management and weight reduction for T1D, MannKind's inhaled insulin Afrezza demonstrated positive results for pediatric patients, and Lilly provided detailed efficacy and safety data for retatrutide in T2D. Amgen also presented data for Repatha, highlighting its effectiveness in lowering LDL-C in high-risk diabetes patients.
Jim Cramer Highlighted 16 Stocks Including Quantinuum, and the Market’s Appetite for New Supply
Jim Cramer highlighted 16 stocks, including Quantinuum, indicating the market's strong appetite for new supply. Among the mentioned stocks is MannKind Corporation (NASDAQ:MNKD), which Cramer described as a "total speculation" for investors looking to balance their portfolios with more earnings-oriented holdings. MannKind specializes in biopharmaceutical products for chronic conditions like diabetes and pulmonary hypertension.
Inhaled insulin data explore options for kids, pregnancy and pump users
MannKind (Nasdaq: MNKD) announced new data for its inhaled insulin, Afrezza, and FUROSCIX, presented at the ADA 2026 Scientific Sessions. The findings highlight Afrezza's benefits for pediatric patients, gestational diabetes, and compatibility with automated insulin delivery systems, reinforcing its safety and efficacy. Additionally, real-world data showed no increased lung cancer incidence with Afrezza and reduced hospitalization rates with FUROSCIX in heart failure patients.
MannKind Corp stock (US5638651064): focus on valuation metrics after recent FDA and partnership news
MannKind Corp shares continue to trade in the lower single digits on Nasdaq, with recent FDA and partnership developments bringing valuation ratios into focus. The company has moved into profitability in the last twelve months, supported by inhaled therapies and collaborations, yet its share price remains relatively low. Investors are scrutinizing how these developments, particularly with Afrezza and new partnered therapies, will impact MannKind's long-term valuation in the US healthcare sector.
MannKind (MNKD) Advances Clinical Trials for Inhaled IPF Therapy
MannKind Corporation (NASDAQ: MNKD) has achieved significant milestones in its clinical program for nintedanib DPI, an inhaled therapy for idiopathic pulmonary fibrosis (IPF). The company completed patient randomization for the US Phase 1b INFLO-1 trial and enrolled the first participant in the global Phase 2 INFLO-2 study. This therapy uses MannKind’s Technosphere technology to deliver medication directly to the lungs, aiming for improved efficacy and reduced side effects compared to existing treatments.
MannKind Corporation Presents New Clinical Data Supporting Afrezza and FUROSCIX at ADA 2026 Scientific Sessions
MannKind Corporation announced new clinical data for its inhaled insulin product, Afrezza, and FUROSCIX at the American Diabetes Association’s 2026 Scientific Sessions. The data highlights Afrezza's pediatric safety, glycemic control, and treatment satisfaction, especially after its recent FDA approval for children and adolescents aged 6 and older with type 1 and type 2 diabetes. Additionally, studies explored Afrezza's use with automated insulin delivery systems and in gestational diabetes, along with a real-world evidence study finding no increased lung cancer risk with inhaled insulin.
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
MannKind Corporation announced that the FDA has approved Afrezza® (insulin human) Inhalation Powder for children and adolescents aged 6 and older with type 1 and type 2 diabetes. This represents the first and only inhaled mealtime insulin option for this age group, offering flexibility and a needle-free alternative to traditional injections. The approval is supported by data from the INHALE-1 clinical trial and aims to improve glycemic control by mimicking the body's natural insulin response.
MannKind tests inhaled IPF drug in global trial, first data Q3 2026
MannKind Corporation announced significant progress in its nintedanib DPI program for idiopathic pulmonary fibrosis (IPF), completing patient randomization in the Phase 1b INFLO-1 study and enrolling the first patient in the global Phase 2 INFLO-2 trial. The company anticipates reporting Phase 1b data in Q3 2026, while the Phase 2 study aims to enroll approximately 210 participants across 85 sites worldwide. This inhaled therapy leverages MannKind's Technosphere technology to deliver nintedanib directly to the lungs, potentially improving tolerability and reducing systemic side effects compared to oral formulations.
FDA approves MannKind’s Afrezza inhaled insulin for children with diabetes
MannKind Corporation announced that the FDA has approved Afrezza (insulin human) Inhalation Powder for use in children and adolescents aged 6 and older with type 1 and type 2 diabetes. This approval fulfills a previous postmarketing requirement and expands Afrezza's use from adults, following a year of 21% revenue growth for the company. Despite recent revenue increases, MannKind reported a non-GAAP net loss in Q1 2026.
FDA clears MannKind (NASDAQ: MNKD) Afrezza use in children 6 and older
MannKind Corporation announced that the FDA has approved its Afrezza (insulin human) Inhalation Powder for children and adolescents aged 6 and older with type 1 and type 2 diabetes. This approval expands Afrezza's market beyond adults and fulfills the final postmarketing requirement from its original 2014 approval. The company highlights a significant potential patient pool of over 350,000 U.S. children and adolescents living with diabetes.
MannKind Corp stock (US5638651064): Afrezza pediatric FDA approval and share price weakness draw focus
MannKind Corp shares experienced a sharp decline on Nasdaq despite receiving FDA approval for pediatric use of its inhaled insulin, Afrezza, for Type 1 and Type 2 diabetes. The stock fell by about 8.1% to USD 3.46, indicating that regulatory success doesn't always lead to immediate stock gains. Analysts like Brandon Folkes from H.C. Wainwright maintain a "buy" rating with a USD 10 price target, suggesting a positive long-term outlook for the biopharmaceutical company as it continues to expand Afrezza's market and leverage its drug-device expertise.
Implications of Pediatric Inhaled Insulin Approval
The FDA has approved MannKind Corporation's Afrezza (insulin human) Inhalation Powder for children aged 6 and older with type 1 and type 2 diabetes, marking a significant advancement in pediatric diabetes care by offering an inhaled alternative to injectables. This approval highlights the intricate manufacturing demands of inhaled biologics, requiring precise control over particle properties and specialized production infrastructure. The expansion of Afrezza's indication also reflects a growing trend and commercial potential for inhaled dry powder therapeutics beyond diabetes.
Inhaled insulin for kids: MannKind hosts call on new Afrezza use
MannKind Corporation announced it will host a conference call on May 29, 2026, to discuss the recent FDA approval of its inhaled insulin Afrezza for children and adolescents aged 6 and older with diabetes. CEO Michael Castagna and SVP Kevin Kaiserman will lead the discussion on this significant development. The company experienced a positive market reaction, with MNKD stock gaining 3.57% on the day the news was published, adding approximately $42 million to its valuation.
FDA approves Afrezza for children and adolescents with diabetes
The FDA has approved MannKind Corp.'s Afrezza, an inhaled insulin, for children and adolescents aged 6 and older with Type 1 or Type 2 diabetes. This marks the first needle-free insulin option for pediatric diabetes patients, offering a rapid-acting solution that can be dosed at the start of a meal to better accommodate variable routines. The approval was based on the INHALE-1 study, which demonstrated Afrezza's non-inferiority to daily insulin injections in glycemic control and showed reassuring pulmonary safety.
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
MannKind Corporation announced it will host a conference call today, May 29, 2026, at 4:30 p.m. Eastern, to discuss the recent FDA approval of Afrezza for diabetic children and adolescents aged 6 and older. CEO Michael Castagna and SVP Kevin Kaiserman will present on the call. A webcast link will be available on the company's investor relations website, with recorded versions accessible for 90 days.
MannKind wins FDA approval for inhaled insulin for children with type 1, type 2 diabetes
MannKind (Nasdaq: MNKD) announced that its Afrezza inhaled insulin powder has received FDA approval for use in children and adolescents aged 6 and older with type 1 and type 2 diabetes. Afrezza is a fast-acting insulin formulation delivered via a mechanical inhaler device that requires no electronics. This approval expands the use of the product to a younger patient population.
FDA Approves Afrezza Insulin Inhalation Powder for Children, Adolescents With Type 1 and Type 2 Diabetes
The FDA has approved Afrezza, an insulin human inhalation powder, for managing type 1 and type 2 diabetes in children and adolescents aged 6 years and older. This expands its previous adult-only indication, offering a non-injectable, ultra-rapid-acting mealtime insulin option. The approval is based on the INHALE-1 clinical trial, which demonstrated non-inferiority in HbA1c and time-in-range compared to rapid-acting analog injections.
MannKind Corporation Announces FDA Approval of Afrezza® Inhalation Powder for Pediatric Use in Type 1 and Type 2 Diabetes
MannKind Corporation received FDA approval for Afrezza® (insulin human) Inhalation Powder for children aged 6 and older with type 1 and type 2 diabetes. This ultra rapid-acting inhaled insulin offers a needle-free, flexible mealtime option, dosing at the start of meals, and is supported by Phase 3 clinical trials. The company emphasizes affordability and patient support through MannKind Cares, while also detailing potential side effects and safety information.
FDA approves first inhaled mealtime insulin for kids 6+
MannKind (Nasdaq: MNKD) announced FDA approval of Afrezza, an inhaled mealtime insulin, for children and adolescents aged 6 and older with type 1 and type 2 diabetes. This ultra rapid-acting, needle-free insulin offers flexibility for managing blood sugar during meals and snacks, and is supported by the Phase 3 INHALE-1 trial. Eligible patients can access Afrezza for $35 or less per month, expanding treatment options for over 350,000 U.S. children with diabetes.
MNKD - Mannkind Corp Stock Price and Quote
This article provides comprehensive financial data, news, and analyst ratings for Mannkind Corp (MNKD). It includes stock performance, key financial metrics, insider transactions, and recent company announcements related to their product Afrezza and other pipeline developments.
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
MannKind Corporation announced it will host a conference call to discuss the recent FDA approval of Afrezza for pediatric use in children and adolescents aged 6 and older with diabetes. The call is scheduled for May 29, 2026, at 4:30 p.m. Eastern, and will feature CEO Michael Castagna and SVP Kevin Kaiserman. A live audio webcast and recorded versions will be available on the company's investor relations website.
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
MannKind Corporation announced that the FDA has approved Afrezza® (insulin human) Inhalation Powder for children and adolescents aged 6 and older with type 1 and type 2 diabetes. This approval provides a needle-free, inhaled mealtime insulin option, allowing for flexible dosing at the start of meals. The decision is supported by the Phase 3 INHALE-1 study and aims to advance pediatric diabetes care by offering a practical solution for daily management.
FDA drops MannKind (NASDAQ: MNKD) Afrezza pulmonary malignancy trial demand
The FDA has released MannKind from a major postmarketing requirement to conduct a five-year study assessing the pulmonary malignancy risk of Afrezza in 8,000-10,000 adults. This significantly reduces the long-term clinical and financial burden for MannKind. The company will now focus on the remaining postmarketing requirement, which is a pediatric study, and awaits a PDUFA target action date of May 29, 2026, for a supplemental Biologics License Application for Afrezza in children and adolescents.
MannKind to Present at Jefferies Global Healthcare Conference
MannKind Corporation (Nasdaq: MNKD) announced that its CEO, Michael Castagna, PharmD, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3. The biopharmaceutical company focuses on cardiometabolic and orphan lung diseases, providing patient-centric solutions. A live audio webcast of the presentation will be available on MannKind's investor relations website.
